P. Sheehy

发表

Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.

L. Cone, F. Eilber, J. Block, 1978, Cancer treatment reports.

Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.

Karan P. Singh, S. Greenland, S. Treon, 2012, Cancer epidemiology.

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

S. Treon, Z. Hunter, R. Ojha, 2011, Clinical lymphoma, myeloma & leukemia.

IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia

S. Treon, Z. Hunter, M. Morra, 2010, Haematologica.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

D. Esseltine, S. Treon, I. Ghobrial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2009, Clinical lymphoma & myeloma.

Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia

D. Skifter, S. Lincoln, J. Laramie, 2011 .

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012, Clinical lymphoma, myeloma & leukemia.

Asynchronous DNA synthesis and asynchronous mitosis in multinuclear ovarian cancer cells.

B. Clarkson, P. Sheehy, R. Winn, 1974, Cancer research.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen

S. Treon, Z. Hunter, L. Ioakimidis, 2011, British journal of haematology.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naı̈ve patients with Waldenstrom Macroglobulinaemia who respond

S. Treon, Z. Hunter, L. Ioakimidis, 2011 .

Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.

N. Barth, S. Selvan, R. Dillman, 2004, Cancer biotherapy & radiopharmaceuticals.

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

N. Harris, D. Skifter, S. Lincoln, 2012, The New England journal of medicine.

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

S. Treon, Z. Hunter, Guang Yang, 2014, Blood.

small somatic deletions associated with B-cell lymphomagenesis characterized by highly recurring MYD 88 and WHIM-like CXCR 4 mutations , The genomic landscape of Waldenstöm ' s Macroglobulinemia

S. Treon, Z. Hunter, Guang Yang, 2013 .

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

S. Treon, I. Ghobrial, Z. Hunter, 2014, Blood.

Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.

S. Treon, L. Ioakimidis, R. Manning, 2011, Clinical lymphoma, myeloma & leukemia.

Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM).

S. Treon, Z. Hunter, L. Ioakimidis, 2010 .

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

P. Richardson, A. Dispenzieri, D. DeAngelo, 2009 .

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.

Hsiuyi Tseng, S. Rodig, S. Treon, 2011, Clinical lymphoma, myeloma & leukemia.

Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

Hsiuyi Tseng, S. Verselis, E. Fox, 2011, British journal of haematology.

macroglobulinemia neuropathy-sparing approach for treating Waldenström's Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a

I. Ghobrial, J. Castillo, Guang Yang, 2014 .

Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.

N. Munshi, S. Treon, M. Fulciniti, 2011, Clinical lymphoma, myeloma & leukemia.

Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia.

S. Treon, L. Ioakimidis, C. Patterson, 2008 .

Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance

S. Treon, Z. Hunter, B. Ciccarelli, 2010 .

Comparative response assessment by total serum IgM and IgM M-component in Waldenstrom’s macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2012 .

Use of whole genome sequencing to identify highly recurrent somatic mutations in Waldenström’s macroglobulinemia.

S. Treon, Z. Hunter, Guang Yang, 2012 .

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration.

S. Treon, Z. Hunter, B. Ciccarelli, 2013, Clinical lymphoma, myeloma & leukemia.

Plenary Paper

S. Treon, Z. Hunter, Guang Yang, 2014 .

Successful Treatment of Transitional Cell Carcinoma of the Urethra with Chemotherapy

R. Dillman, P. Sheehy, L. Vandermolen, 2002, Cancer investigation.